Table of contents
The Ethical Case for Regulation
What we owe people we know will use drugs.
Executive Summary
This chapter is the ethical case for regulation. It is not a claim that drug use is good.
We regulate risky realities because we know people will keep doing them. We regulate cars because people will keep driving. We regulate alcohol because people will keep drinking. We regulate pharmaceuticals because people will keep needing medication. Pretending risk doesn’t exist is not moral clarity. It is negligence.
Drugs should not be the exception.
We already know drug use exists at scale. SAMHSA’s 2022 National Survey on Drug Use and Health reports 48.7 million people aged 12+ had a substance use disorder in the past year (17.3%).[1] We also know the overdose baseline is still massive: CDC reports 79,384 overdose deaths in 2024.[2] We know the addiction treatment gap is huge: in 2022, 54.6 million people needed substance use treatment, but only 13.1 million received it.[3] And we know effective medical responses are underused: NIDA says fewer than 1 in 5 people with opioid use disorder receive medications for opioid use disorder that reduce overdose risk.[4]
So drug legalization ethics starts with one uncomfortable truth: some people you know will use drugs.
The ethical question is not, “How do we punish our way to a drug-free society?”
The ethical question is: what do we owe people we know will use drugs—especially when our policy choices affect whether they live long enough to recover?
This post argues that:
• harm reduction ethics creates duties to prevent preventable death (naloxone, medication, safer-use infrastructure).
• drug policy reform needs public safety and accountability, not slogans.
• risk-based drug regulation is the ethical guardrail: tighter rules where risk is highest.
• the regulated pharmacy model is a narrow, high-structure lane for the highest-risk reality.
• policy evaluation is part of ethics: fund what works, stop funding what doesn’t.
Direct Answer
The ethical case for drug regulation starts with a known reality: millions of people will use drugs, and policy choices affect whether they live long enough to recover. Pretending a drug-free society through punishment is negligence when overdose deaths, treatment gaps, and underused medications for opioid use disorder remain massive. Harm reduction ethics creates duties to prevent preventable death through naloxone, treatment access, and safer infrastructure. Risk-based regulation with public safety guardrails is what we owe people we know will use drugs.
Assumptions (brief)
• U.S.-centered. Evidence and guidance from CDC, NIDA, HHS, WHO, and EUDA are used to ground the practical ethics.
• The aim is fewer funerals, less stigma reduction failure, and stronger public safety outcomes.
Where This Sits in the Series
• Part 1 — series overview
• Part 1.5 — definitions
• Part 2 — drug felony consequences and the underclass
• Part 3 — drug felony voting and gun rights consequences
• Part 4 — benefits of legalization and regulation
• Part 5 — black-market incentives and violence
• Part 6 — emerging mixtures and analogues
• Part 7 — funding and the recovery lockbox
• Part 8 — fear-based policy failure
• Part 9 — risk-based drug regulation
• Part 10 — accountability boundaries
• Part 11 — evidence-based prevention
• Part 12 — post-release overdose risk
• Part 13 — addiction and homelessness
• Part 14 — regulated pharmacy model
• Part 15 — the hard objections
• Part 16 — pilot, measure, scale
• Part 17 — case studies
• Part 18 — public health framing
• Part 19 — regulation is already administered
• Part 20 — urgency without panic
• Part 21 — bipartisan viability
• Part 22 — how buy-in changes
• Part 23 — projecting the status quo forward
Drug Legalization Ethics Starts With Honesty: People Will Use Drugs
Drug legalization ethics begins with reality, not with slogans.
We do not have a policy choice between “drug use” and “no drug use.” We have a policy choice between an unregulated supply chain and a regulated one, between reachability of treatment on demand and rationed access, between repeated stigma and practical exits.
SAMHSA’s NSDUH data show substance use disorder exists at scale.[1] CDC’s overdose baseline shows preventable death exists at scale.[2] In that world, the ethical question becomes unavoidable:
If we know people will use drugs, are we comfortable outsourcing their safety to a market that has no labeling, no standards, no recall system, and no accountability?
That outsourcing is not passive. It is an active choice.
This is why Part 1 set the tone: drug legalization isn’t endorsement; it’s harm reduction and regulation.
And why Part 1.5 matters: legalization vs decriminalization vs regulation is the difference between “stop punishing” and “start governing.”
Ethically, the baseline duty is simple: reduce predictable harm where you can, and do not pretend denial is a strategy.
The same logic applies across society. Human dignity doesn’t disappear because a behavior makes us uncomfortable. We don’t abolish seatbelts to “discourage driving.” We regulate driving because we know driving will happen.
That is what drug legalization ethics is pointing at: govern reality.
The Ethical Case for Regulation: What the Status Quo Chooses
The ethical case for regulation is strongest when you stop treating the status quo as morally neutral.
Status quo drug policy tolerates predictable harms:
• Overdose deaths are still mass death. CDC reports 79,384 overdose deaths in 2024.[2]
• Treatment access is still rationed. CDC reports 54.6 million needed treatment in 2022, while only 13.1 million received it.[3]
• Evidence-based medication is still underused. NIDA says fewer than 1 in 5 people with opioid use disorder receive medications that reduce overdose risk.[4]
• Stigma is still a barrier. CDC explicitly says stigma makes it harder for people with substance use disorders to get help.[3]
This is why harm reduction ethics exists: it rejects the idea that abstinence must come first before survival.
HHS’s overdose prevention strategy includes harm reduction and frames it as increasing availability of harm reduction services while reducing stigma related to substance use and overdose.[5] That is public health drug policy acknowledging a basic ethical duty: stop making people die to prove a point.
The status quo also produces collateral harms that are not “side effects.” They are built into criminal branding. The series has already documented this underclass machinery in Part 2 and Part 3.
Ethics has to account for those predictable outcomes too.
At minimum, drug policy reform should be judged on whether it reduces: preventable death, avoidable disease, avoidable incarceration churn, and lifelong collateral punishment.
That’s outcomes ethics.
Harm Reduction Ethics: What We Owe People Right Now
This is not sentimental. It is operational.
It asks: what prevents a funeral this week?
Naloxone
FDA approved the first over-the-counter naloxone nasal spray and describes naloxone as a standard treatment that rapidly reverses opioid overdose.[6] If naloxone reverses overdose, then naloxone distribution becomes a duty, not a political preference.
Medication for opioid use disorder
NIDA emphasizes that medications for opioid use disorder are effective and reduce overdose death risk, yet they remain underused.[4] Harm reduction ethics says medication access should be easy to start and easy to continue.
Syringe services programs
WHO’s 2026 operational guide provides practical guidance for scaling needle and syringe programmes in comprehensive harm reduction responses.[7] WHO also highlights that injecting drug use contributes to HIV and HCV burden globally.[8] Syringe services programs are part of public safety because disease outbreaks and discarded equipment are public safety issues.
Supervised consumption sites
EUDA summarizes that drug consumption rooms aim to prevent overdose deaths and connect high-risk users with treatment and health services.[9] A Lancet study found the fatal overdose rate decreased more in the area near Vancouver’s supervised injecting facility after opening compared to the rest of the city.[10]
None of this requires pretending drug use is harmless.
Harm reduction ethics simply refuses to confuse “I disapprove” with “I should block life-saving tools.”
That’s also why Part 18 in this series framed public health drug policy as the alternative to moral panic.
And why Part 20 framed urgency without panic.
Ethical Frameworks Behind Drug Legalization Ethics
Drug legalization ethics is easier to defend when you name the ethical framework instead of pretending your intuition is universal.
| Framework | Core claim | Policy implication | Strengths | Weaknesses |
|---|---|---|---|---|
| Utilitarian | Choose the policy that reduces total harm and increases well-being. | Prioritize overdose prevention, treatment on demand, and harm reduction when they reduce deaths and disease. | Outcome-focused; matches public health drug policy. | Can be abused to ignore individual rights. |
| Deontological (duty-based) | We have duties not to knowingly impose avoidable harm. | Stop policies that predictably produce preventable death and long-term collateral damage; treat the ethical argument for regulation as duty. | Clear boundaries; resists punishment theater. | Rigid when duties conflict (autonomy vs protection). |
| Rights-based | People retain human dignity and basic rights even when they make risky choices. | Reduce criminal branding; expand medication for opioid use disorder; protect privacy; reduce stigma reduction barriers. | Centers human dignity and fairness. | Rights conflicts can slow decisions without clear prioritization. |
| Public health pragmatism | Reduce preventable death and disease using evidence, even if behavior persists. | Scale naloxone, syringe services programs, supervised consumption sites where feasible, and treatment on demand; regulate risk by tier. | Evidence-aligned; scalable; less ideological. | Can be misread as permissive unless accountability is explicit. |
Most people don’t hold just one of these frameworks. They hold a mix.
That’s why the ethical case for regulation can be strong across political identities: fewer deaths, less stigma, less underclass damage, and clearer public safety priorities.
Part 21 covers the bipartisan angle.
Risk-Based Drug Regulation and the Regulated Pharmacy Model
Ethics fails when it refuses to discriminate between risks.
Risk-based drug regulation is the ethical solution to that problem: the tighter the risk, the tighter the lane.
This matters because “legalization” is not one policy. It is a set of lanes.
Risk-based drug regulation means:
• lower-risk products: tighter-than-tobacco rules, age limits, packaging, enforcement against sales to minors
• higher-risk products: clinical access, monitoring, and strict accountability
• highest-risk reality: a regulated pharmacy model with audits, documentation, and direct links to treatment on demand
That is why the regulated pharmacy model exists in this series: Part 14.
A regulated pharmacy model is ethically defensible because it aligns safety with structure:
• clinical oversight
• limited and auditable access
• continuous diversion control monitoring
• explicit public safety enforcement against fraud, violence, and trafficking outside regulated channels
• accountability when rules are violated
Diversion control is the community-protection requirement. Without diversion control, you create new harm. With diversion control, you create governable lanes.
This is also why Part 19 mattered: regulation is already being administered in controlled substance systems, and complexity is not the real barrier.[13]
If you want the enforcement boundaries that remain in place, Part 10 lays them out.
Implementation Ethics: Policy Evaluation and Treating Measurement as a Moral Duty
If ethics is real, it has to show up as measurement.
Policy evaluation is not a bureaucratic add-on. It is how you prove you are reducing harm and not just moving it around.
Oregon’s Measure 110 audit is a cautionary example of what happens when a public-health vision is not matched with stability, coordination, and clear results.[11] Ethical policy has to survive politics, which means it has to be measurable.
Measurement problems also show up inside treatment.
A systematic review in Drug and Alcohol Review found that 32% of studies had no definition of “relapse,” and operationalisations varied widely.[12] That supports a harsh point: if the field can’t define relapse consistently, it becomes easier to fund ineffective programs while calling them “evidence-based.”
So implementation ethics requires:
• treatment on demand capacity
• standardized outcomes tracking (initiation, engagement, retention)
• transparent dashboards
• funding tied to outcomes, not vibes
| Metric | People (millions) | Source |
|---|---|---|
| Needed substance use treatment (past year, 2022) | 54.6 | CDC stigma reduction |
| Received substance use treatment (past year, 2022) | 13.1 | CDC stigma reduction |
| Addiction treatment gap (computed) | 41.5 | Computed from CDC numbers |
Source: CDC stigma reduction.[3]
Ethically, that gap is the difference between “care exists” and “care is reachable.”
Part 16 is the series’ operating model for making change without betting the farm.
Ethical Implementation Steps: A 12-Month Plan That Builds Trust
The ethical case for regulation has to turn into a plan that ordinary people can trust.
gantt
title Part 24: Ethical Implementation (12 Months)
dateFormat YYYY-MM-DD
section Define duties and guardrails
Publish ethics charter (drug legalization ethics + accountability) :a1, 2026-04-01, 30d
Define metrics + policy evaluation dashboard :a2, 2026-04-01, 45d
Set diversion control rules + enforcement boundaries :a3, 2026-04-15, 45d
section Expand what saves lives now
Naloxone access expansion plan :b1, 2026-05-01, 90d
Medication for opioid use disorder access protocols :b2, 2026-05-01, 120d
Low-barrier intake (treatment on demand pathways) :b3, 2026-05-15, 150d
section Pilot high-risk lanes ethically
Regulated pharmacy model pilot (eligibility + audits) :c1, 2026-08-01, 120d
Monthly public reporting + community review :c2, 2026-09-01, 180d
section Decide
Independent review: scale / tighten / stop :d1, 2027-01-15, 45d
This is how you build public buy-in without moral panic: guardrails first, transparency always.
Part 22 explains why public buy-in is built, not waited for.
The Bottom Line
Drug legalization ethics is not “approve drugs.”
It is “stop manufacturing preventable death.”
We know people will use drugs. We know overdose death remains high. We know medication and treatment are under-delivered. We know stigma reduction failures block care. We know black markets don’t self-regulate.
So the ethical case for regulation is this:
• apply harm reduction ethics so people live long enough to recover
• expand treatment on demand and medication for opioid use disorder
• use risk-based drug regulation so rules match risk
• use a regulated pharmacy model for the highest-risk lane
• make diversion control, public safety, accountability, and policy evaluation visible
That is what we owe people we know will use drugs.
Frequently Asked Questions
Is drug legalization ethics compatible with public safety?
Yes. Drug legalization ethics still enforces violence, fraud, trafficking outside regulated channels, sales to minors, and impaired driving. That’s accountability, not permissiveness.
What does harm reduction ethics mean in one sentence?
Harm reduction ethics means you don’t withhold life-saving tools until people meet a moral threshold.
Why mention supervised consumption sites?
Because EUDA notes these services aim to prevent overdose deaths and connect people to treatment.[9] Evidence includes peer-reviewed findings like reduced overdose mortality near Vancouver’s facility after opening.[10]
Why does measurement matter ethically?
Because policy evaluation is how you prove you are reducing harm and not funding failure. The relapse-definition inconsistency in research is one example of why standardization matters.[12]
Frequently Asked Questions
What is the ethical case for drug regulation?
The ethical case starts from known use at scale, overdose deaths, and a large treatment gap. When people will keep using drugs, policy that outsources safety to a black market is negligence. Regulation with harm reduction and accountability is what we owe people who may still need a path to recovery.[1][2][3]
Does arguing for regulation mean drug use is good?
No. This chapter argues that use is a known reality, not a virtue. The duty is to reduce preventable death and strengthen public safety, not to celebrate use.
How do harm reduction ethics and accountability fit together?
Harm reduction ethics creates duties to prevent preventable death (naloxone, treatment access, safer infrastructure). Accountability and risk-based rules keep reform from becoming a slogan without enforcement, measurement, or public safety guardrails.
Why is policy evaluation part of ethics?
Funding what does not work while underfunding what does is itself an ethical failure. Measurement and willingness to stop failed programs are part of what we owe the people those programs claim to serve.[11]
References
[1] SAMHSA. 2022 NSDUH Main Highlights (PDF). https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-nsduh-main-highlights.pdf
[2] CDC NCHS. Drug Overdose Deaths in the United States, 2023–2024 (NCHS Data Brief No. 549). https://www.cdc.gov/nchs/products/databriefs/db549.htm
[3] CDC. Stigma Reduction | Stop Overdose (2022 treatment need vs received). https://www.cdc.gov/stop-overdose/stigma-reduction/index.html
[4] NIDA. Medications for Opioid Use Disorder. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
[5] HHS. Harm Reduction | Overdose Prevention Strategy. https://www.hhs.gov/programs/overdose-prevention.html
[6] FDA. FDA Approves First Over-the-Counter Naloxone Nasal Spray (GovDelivery bulletin). https://content.govdelivery.com/accounts/USFDA/bulletins/351b34d
[7] WHO. Needle and syringe programmes for people who inject drugs: operational guide (2026). https://www.who.int/publications/i/item/9789240116214
[8] WHO. People who inject drugs (HIV/HCV burden). https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/populations/people-who-inject-drugs
[9] EUDA. Drug consumption rooms: an overview of provision and evidence (Perspectives on drugs). https://www.euda.europa.eu/publications/pods/drug-consumption-rooms_en
[10] The Lancet. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility (2011). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962353-7/abstract
[11] Oregon Secretary of State Audits Division. Measure 110 Lacks Stability, Coordination, and Clear Results (Report 2025-29) (PDF). https://sos.oregon.gov/audits/Documents/2025-29.pdf
[12] Moe FD, et al. Is the relapse concept in studies of substance use disorders a “one size fits all” concept? A systematic review of relapse operationalisations. Drug and Alcohol Review (2022). https://pubmed.ncbi.nlm.nih.gov/34792839/
[13] DEA Diversion Control Division. Pharmacist’s Manual (closed system of distribution). https://www.deadiversion.usdoj.gov/GDP/%28DEA-DC-046R1%29%28EO-DEA154R1%29_Pharmacist%27s_Manual_DEA.pdf
If you want to follow the full series as it publishes, visit the full Drug Legalization Series. If you prefer audio conversations on recovery, reentry, and purpose, check the podcast page. For program directors building reentry and transition programming, see ReturnPath reentry curriculum. For the personal story behind this work, read A Vision of Hope. To invite Andrew for a keynote or panel, see speaking.